Treatment and Prevention of Kidney Stones: An Update



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2011 Dec 1;84(11):1234-1242.

  Patient information: See related handout on preventing kidney stones, written by the authors of this article.

  Related letter: NSAIDs for Relieving Renal Colic in Patients with Kidney Stones

The incidence of nephrolithiasis (kidney stones) is rising worldwide, especially in women and with increasing age. Kidney stones are associated with chronic kidney disease. Preventing recurrence is largely specific to the type of stone (e.g., calcium oxalate, calcium phosphate, cystine, struvite [magnesium ammonium phosphate]), and uric acid stones); however, even when the stone cannot be retrieved, urine pH and 24-hour urine assessment provide information about stone-forming factors that can guide prevention. Medications, such as protease inhibitors, antibiotics, and some diuretics, increase the risk of some types of kidney stones, and patients should be counseled about the risks of using these medications. Managing diet, medication use, and nutrient intake can help prevent the formation of kidney stones. Obesity increases the risk of kidney stones. However, weight loss could undermine prevention of kidney stones if associated with a high animal protein intake, laxative abuse, rapid loss of lean tissue, or poor hydration. For prevention of calcium oxalate, cystine, and uric acid stones, urine should be alkalinized by eating a diet high in fruits and vegetables, taking supplemental or prescription citrate, or drinking alkaline mineral waters. For prevention of calcium phosphate and struvite stones, urine should be acidified; cranberry juice or betaine can lower urine pH. Antispasmodic medications, ureteroscopy, and metabolic testing are increasingly being used to augment fluid and pain medications in the acute management of kidney stones.

The prevalence of nephrolithiasis (kidney stones) is increasing in women and with increasing age. The risk of developing kidney stones is 10 to 15 percent in the United States, although this number is trending higher.13  Table 1 includes rates of different types of kidney stones in children and adults.48 Contributing risk factors for kidney stones are obesity, insulin resistance, gastrointestinal pathology, living in warmer climates, and certain dietary patterns and medications.2,9

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendations Evidence rating References

Patients with kidney stones should increase fluid intake to at least 2 L per 24 hours.

B

29, 30, 32

Kidney stone type should be identified when possible, even on initial stone occurrence.

C

10, 31

Urine characteristics (e.g., urine pH) should be obtained in patients with kidney stones to guide treatment and prevention.

C

10, 22, 31, 46

Patients with kidney stones should be counseled on stone-specific dietary interventions.

C

28, 30, 42, 43

Patients with kidney stones should be assessed for risk of chronic kidney disease.

C

5, 26

To prevent kidney stones, medication use should be evaluated and modified as needed.

C

1517, 19, 21


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendations Evidence rating References

Patients with kidney stones should increase fluid intake to at least 2 L per 24 hours.

B

29, 30, 32

Kidney stone type should be identified when possible, even on initial stone occurrence.

C

10, 31

Urine characteristics (e.g., urine pH) should be obtained in patients with kidney stones to guide treatment and prevention.

C

10, 22, 31, 46

Patients with kidney stones should be counseled on stone-specific dietary interventions.

C

28, 30, 42, 43

Patients with kidney stones should be assessed for risk of chronic kidney disease.

C

5, 26

To prevent kidney stones, medication use should be evaluated and modified as needed.

C

1517, 19, 21


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Table 1.

Incidence of Kidney Stones in Children and Adults

Type Children (%) Adult (%)

Calcium oxalate

45 to 65

56 to 61

Calcium phosphate

24 to 30

8 to 18*

Cystine

5 to 8

1

Struvite (magnesium

7 to 13

2 to 4

ammonium phosphate)

Uric acid

2 to 4

9 to 17

Other

4

2


*—Incidence is as high as 75 percent in pregnant women.4

Information from references 4 through 8.

Table 1.   Incidence of Kidney Stones in Children and Adults

View Table

Table 1.

Incidence of Kidney Stones in Children and Adults

Type Children (%) Adult (%)

Calcium oxalate

45 to 65

56 to 61

Calcium phosphate

24 to 30

8 to 18*

Cystine

5 to 8

1

Struvite (magnesium

7 to 13

2 to 4

ammonium phosphate)

Uric acid

2 to 4

9 to 17

Other

4

2


*—Incidence is as high as 75 percent in pregnant women.4

Information from references 4 through 8.

Acute Diagnosis and Management

CLINICAL PRESENTATION

The characteristic cramping and intermittent abdominal and flank pain occur as kidney stones travel within the urinary tract. The pain is often accompanied by hematuria, nausea or vomiting, and malaise; fever and chills may also be present. However, stones in the renal pelvis may be asymptomatic. The differential diagnosis includes infections in the urinary tract or abdomen, malignancies, and musculoskeletal inflammation or spasm (Table 2).9

Table 2.

Differential Diagnosis of Urinary Calculi

Clinical clues Suggested diagnoses

Dysuria

Urinary tract infection, interstitial cystitis (pelvic pain syndrome), vaginitis, prostatitis

Fevers, chills

Nonspecific response to infection or inflammation

Frequency

High fluid intake, urinary tract infection, bladder spasms, benign prostatic hyperplasia, hyperglycemia

Hematuria

Kidney stones, uroepithelial or prostatic tumors, urinary tract infection, renal glomerular disease

Nausea, vomiting

Nonspecific response to pain, intestinal or urinary obstruction, gastrointestinal disease

Pain and tenderness

Abdominal

Kidney stones, gastrointestinal disease

Flank

Kidney stones, musculoskeletal inflammation or spasm, referred pain from gallbladder (on right side), pyelonephritis

Groin or pelvic

Kidney or bladder stones, urethritis, prostatitis, vaginitis, pelvic inflammatory disease, pelvic pain syndrome


Adapted from Pietrow PK, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. 2006;74(1):88.

Table 2.   Differential Diagnosis of Urinary Calculi

View Table

Table 2.

Differential Diagnosis of Urinary Calculi

Clinical clues Suggested diagnoses

Dysuria

Urinary tract infection, interstitial cystitis (pelvic pain syndrome), vaginitis, prostatitis

Fevers, chills

Nonspecific response to infection or inflammation

Frequency

High fluid intake, urinary tract infection, bladder spasms, benign prostatic hyperplasia, hyperglycemia

Hematuria

Kidney stones, uroepithelial or prostatic tumors, urinary tract infection, renal glomerular disease

Nausea, vomiting

Nonspecific response to pain, intestinal or urinary obstruction, gastrointestinal disease

Pain and tenderness

Abdominal

Kidney stones, gastrointestinal disease

Flank

Kidney stones, musculoskeletal inflammation or spasm, referred pain from gallbladder (on right side), pyelonephritis

Groin or pelvic

Kidney or bladder stones, urethritis, prostatitis, vaginitis, pelvic inflammatory disease, pelvic pain syndrome


Adapted from Pietrow PK, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. 2006;74(1):88.

DIAGNOSTIC WORKUP

The initial workup of a patient with suspected kidney stones (Figure 1) should include urinalysis for blood. Urine cultures are crucial if the patient is febrile or leukocytes are detected in the urine. Diagnosis is sometimes made by visualizing a stone on a plain radiograph. Uric acid stones and stones associated with protease inhibitor use may not be visible on a radiograph. Ultrasonography or spiral computed tomography can detect all types of kidney stones and may be necessary if the diagnosis is in question.

Diagnosis and Management of Acute Kidney Stones

Figure 1.

Algorithm for the diagnosis and management of acute kidney stones.

View Large

Diagnosis and Management of Acute Kidney Stones


Figure 1.

Algorithm for the diagnosis and management of acute kidney stones.

Diagnosis and Management of Acute Kidney Stones


Figure 1.

Algorithm for the diagnosis and management of acute kidney stones.

Referral to a urologist is warranted when more than one stone is present, symptoms worsen with fever, renal function is impaired, stone passage is prolonged, hydronephrosis is diagnosed based on imaging findings, the patient is pregnant, or the stone is larger than 5 mm in diameter as measured using computed tomography or ultrasonography. Smaller stones pass spontaneously in 90 percent of patients.10 Urologists are increasingly using ureteroscopy to remove stones and evaluate for changes in the uroepithelial lining.11 Interstitial deposits containing calcium oxalate (Randall plaques) are visible on ureteroscopy as whitish deposits.12

MANAGEMENT

Oral hydration and pain management are part of the acute treatment of all stone types (Table 31,9,10,13 and Figure 1). For stones measuring 10 mm or less, antispasmodics such as calcium channel blockers and alpha blockers relax the smooth muscle of the ureters and have been shown to hasten stone passage by five to seven days.10 Coadministration of oral corticosteroids leads to little or no improvement in outcomes.14 Patients who are unable to take oral fluids or medications and patients with low blood pressure or other signs of early hemodynamic instability should be treated intravenously. If signs of possible infection are present (e.g., fever, pyuria), initial management should include empiric antibiotics that cover gram-negative bacilli (e.g., Enterobacteriaceae species) and gram-positive cocci (e.g., staphylococci, enterococci) according to local susceptibility patterns. Referral to a urologist should be expedited if the patient also shows radiologic evidence of obstruction (hydronephrosis).

Table 3.

Acute Management of Kidney Stones in Adults

Management type Therapy Dosage

Fluids

Oral intake of water, or intravenous normal saline if patient is unable to take oral fluids

At least 2 L of water per 24 hours

0.9% normal saline solution if blood pressure is low; consider decreasing sodium chloride in patients with calciuria (5% dextrose in water and 0.45% normal saline)

Antispasmodics to facilitate stone passage*

Alpha blockers

Doxazosin (Cardura)

4 mg orally per day

Tamsulosin (Flomax)

0.4 mg orally per day

Calcium channel blockers

Nifedipine (Procardia, sustained release)

30 mg orally per day

Pain management†

Opioid narcotics

Codeine/acetaminophen

One or two tablets (5 to 10 mg codeine/325 to 500 mg acetaminophen) orally every four to six hours as needed

Hydrocodone/acetaminophen (Vicodin)

5 to 10 mg orally every four to six hours as needed


note: Patients who are unable to take oral medications and patients with low blood pressure or other signs of early hemodynamic instability should be treated intravenously.

*—Often administered for up to four weeks before performing follow-up imaging studies to determine whether the stone has passed.

†—Avoid using nonsteroidal anti-inflammatory drugs because they tend to lower kidney blood flow and glomerular filtration.

Information from references 1, 9, 10, and 13

Table 3.   Acute Management of Kidney Stones in Adults

View Table

Table 3.

Acute Management of Kidney Stones in Adults

Management type Therapy Dosage

Fluids

Oral intake of water, or intravenous normal saline if patient is unable to take oral fluids

At least 2 L of water per 24 hours

0.9% normal saline solution if blood pressure is low; consider decreasing sodium chloride in patients with calciuria (5% dextrose in water and 0.45% normal saline)

Antispasmodics to facilitate stone passage*

Alpha blockers

Doxazosin (Cardura)

4 mg orally per day

Tamsulosin (Flomax)

0.4 mg orally per day

Calcium channel blockers

Nifedipine (Procardia, sustained release)

30 mg orally per day

Pain management†

Opioid narcotics

Codeine/acetaminophen

One or two tablets (5 to 10 mg codeine/325 to 500 mg acetaminophen) orally every four to six hours as needed

Hydrocodone/acetaminophen (Vicodin)

5 to 10 mg orally every four to six hours as needed


note: Patients who are unable to take oral medications and patients with low blood pressure or other signs of early hemodynamic instability should be treated intravenously.

*—Often administered for up to four weeks before performing follow-up imaging studies to determine whether the stone has passed.

†—Avoid using nonsteroidal anti-inflammatory drugs because they tend to lower kidney blood flow and glomerular filtration.

Information from references 1, 9, 10, and 13

Further Evaluation

Further evaluation identifies modifiable risk factors and guides individualized treatment and prevention. The medical history should identify conditions associated with increased risk of kidney stones (e.g., inflammatory bowel disease, bowel surgery, gout, diabetes mellitus, obesity or recent changes in weight, metabolic syndromes, hyperparathyroidism-associated conditions, frequent urinary tract infections, chronic kidney disease).15 A family medical history should also be obtained.

A medication history establishes temporal associations; identifies medications recently discontinued, off-label use of medications, and use of herbal preparations and supplements; and screens for illicit drug use. Medications contribute to kidney stones (Table 4) through various mechanisms by forming urine crystals and altering urine characteristics (e.g., changing urine pH, reducing urine volume).1623 For example, carbonic anhydrase inhibitors contribute to calcium phosphate stone formation by causing a mild systemic acidosis and paradoxically high urine pH, hypercalciuria, and low urine citrate.22,23 Some antibiotics may increase urine oxalate by reducing the intestinal bacteria that break down oxalate.

Table 4.

Medications Associated with Kidney Stone Formation

Type of medication Examples

Agents that decrease uric acid production [corrected]

Allopurinol (Zyloprim)

Laxatives (specific to ammonium urate stones), especially if abused

Overuse of any laxative resulting in electrolyte losses

Antibiotics

Sulfonamides, ampicillin, amoxicillin, ceftriaxone (Rocephin), quinolones, furans, pyridines

Carbonic anhydrase inhibitors

Acetazolamide, topiramate (Topamax)

Ephedra alkaloids (banned in the United States)

Herbal products used as stimulants and appetite suppressants

Potassium channel blockers

Amiodarone, sotalol (Betapace), dalfampridine (Ampyra; multiple sclerosis therapy)

Potassium-sparing diuretics

Triamterene (Dyrenium)

Reverse transcriptase inhibitors and protease inhibitors

HAART (highly active antiretroviral therapy)

Sulfonylureas

Various therapies for type 2 diabetes mellitus


Information from references 16 through 23.

Table 4.   Medications Associated with Kidney Stone Formation

View Table

Table 4.

Medications Associated with Kidney Stone Formation

Type of medication Examples

Agents that decrease uric acid production [corrected]

Allopurinol (Zyloprim)

Laxatives (specific to ammonium urate stones), especially if abused

Overuse of any laxative resulting in electrolyte losses

Antibiotics

Sulfonamides, ampicillin, amoxicillin, ceftriaxone (Rocephin), quinolones, furans, pyridines

Carbonic anhydrase inhibitors

Acetazolamide, topiramate (Topamax)

Ephedra alkaloids (banned in the United States)

Herbal products used as stimulants and appetite suppressants

Potassium channel blockers

Amiodarone, sotalol (Betapace), dalfampridine (Ampyra; multiple sclerosis therapy)

Potassium-sparing diuretics

Triamterene (Dyrenium)

Reverse transcriptase inhibitors and protease inhibitors

HAART (highly active antiretroviral therapy)

Sulfonylureas

Various therapies for type 2 diabetes mellitus


Information from references 16 through 23.

Management and prevention are largely specific to the type of kidney stone. However, stones often pass without being retrieved, even when urine is strained. With the increasing incidence and prevalence of kidney stones and chronic kidney disease, further evaluation after a first kidney stone may be beneficial in all patients.24 Risk factors for kidney stone formation can often be assessed even after the stone has passed, through urine and blood chemistry.

Urine pH is an important factor in the production of kidney stones. Uric acid, cystine, and calcium oxalate stones tend to form in acidic urine, whereas struvite (magnesium ammonium phosphate) and calcium phosphate stones form in alkaline urine. A 24-hour urine collection can be analyzed for calcium, phosphorus, magnesium, uric acid, and oxalate to determine stone composition, and for the stone-inhibiting factors citrate and phytate. Urine calcium excretion is another important risk factor for stone formation and is elevated with increased diet acid loads, increased salt intake, and both inadequate and excessive vitamin D levels. Elevated serum calcium levels may suggest primary hyperparathyroidism as the cause of calcium stone formation.

Kidney stones are a risk factor for chronic kidney disease and progression to end-stage renal disease. 5 Persons with kidney stones are more likely to have traditional risk factors for chronic kidney disease (e.g., hypertension, preexisting kidney disease, diabetes, proteinuria, albuminuria), as well as non-traditional factors (e.g., interstitial nephritis, chronic pyelonephritis, female sex). 25 [corrected] The American Society of Nephrology suggests referral to a nephrologist if the estimated glomerular filtration rate is 60 mL per minute per 1.73 m2 or less (stage 3 chronic kidney disease) or if macroalbuminuria is present.26

Special Considerations

CHILDREN

More children are developing kidney stones, which is attributed to the corresponding rise in diabetes, obesity, and hypertension in this population.2,3 Because increasing age is a risk factor for kidney stones, adolescents are more likely to form stones than younger children. The underlying causes and resulting treatments differ in children and adults. Children with kidney stones are more likely to have anatomic and metabolic abnormalities,3 increased urinary calcium excretion, decreased urinary oxalate and citrate excretion, and much higher urinary calcium oxalate saturations than children with no history of kidney stones.2 Children with cystinuria and other hereditary forms of kidney stones are at increased risk of decline in renal function compared with age-matched controls, although progression to end-stage renal disease is uncommon.2

PREGNANT WOMEN

Pregnant women are twice as likely to have calcium phosphate stones compared with age-matched nonpregnant women, and are two to three times more likely to have calcium phosphate stones than oxalate stones.4 The incidence of kidney stones during pregnancy increases in the second and third trimesters. Women have an increased glomerular filtration rate and higher urinary calcium excretion throughout pregnancy, with higher urine pH in the second and third trimesters, which may predispose them to calcium phosphate stones. Ultrasonography is considered the imaging modality of choice in pregnant women. Kidney stones during pregnancy increase the risk of urinary tract infections, and pregnant women with renal colic have nearly double the risk of pre-term delivery compared with women who do not have kidney stones.27

Prevention

Measures to prevent kidney stones include dietary modifications, nutritional supplements, and medications, depending on the specific type of kidney stone and urine characteristics (Table 5).13,2833 General concepts on prevention are presented below.

Table 5.

Recommendations for the Management of Kidney Stones Based on Stone Type and Urine Properties

Stone type Diagnostic evaluation Interventions Recommendations Comments

All types

Urine specific gravity > 1.015

Fluid intake (mostly water)

Drink at least 2 L of water per 24 hours

Consider mineral waters, depending on the type of stone

Mineral content of thousands of mineral waters listed at http://www.mineralwaters.org

Body mass index > 25 kg per m2

Weight loss

Promote a healthy diet and exercise

Fasting serum glucose level > 105 mg per dL (5.83 mmol per L), random level > 140 mg per dL (7.77 mmol per L)

Suggestive of insulin resistance or early diabetes mellitus

Promote low-glycemic diet (normal range is laboratory-dependent)

Serum calcium level > 10 mg per dL (2.50 mmol per L)

Consider primary hyperparathyroidism: check intact parathyroid hormone level

Urine pH (dipstick or from 24-hour urine)

Alkalinize urine (i.e., increase urine pH to 6.5 to 7) with dietary changes or oral supplementation, or until 24-hour urine citrate levels are in the normal range

Alkalinize

Potassium citrate: 10 to 20 mEq orally with meals (prescription required)

Calcium citrate: two 500-mg tablets per day with meals (each tablet contains 120 mg of calcium and 6 mEq of bicarbonate)

Acidify urine (i.e., lower urine pH to 7 or less) with dietary changes or oral supplementation

Acidify

Cranberry juice: at least 16 oz per day

Betaine: 650 mg orally three times per day with meals

Calcium oxalate

Stone analysis, if possible

Appropriate protein intake (< 30 percent of total caloric intake)

Take at least 250 mg per dose, or total calcium > 850 mg per day with meals

Thiazide diuretics (e.g., hydrochlorothiazide): 25 to 50 mg per day

Vitamin D increases intestinal calcium absorption, and renal calcium and phosphate absorption

Calcium supplements (calcium citrate is preferred if also trying to raise urine citrate levels)

Check serum 25-hydroxyvitamin D levels (low limit < 30 ng per mL [74.88 nmol per L])

Thiazide diuretics

24-hour urine oxalate: upper level > 40 mg per day

Diet with moderate amount of fruits and vegetables (do not restrict calcium)

Restrict high oxalate foods (more than 6 mg per serving), such as beans, spinach, rhubarb, chocolate, wheat, nuts, and berries

Magnesium potassium citrate: two tablets three times per day with meals (each tablet contains 3 mEq of magnesium, 7 mEq of potassium, and 10 mEq of citrate)

Limit vitamin C to less than 1 g per day

Oxalate restriction is minimally effective and applies primarily to those with genetic mutations in the oxalate transporters

Consider magnesium potassium citrate supplementation

Encourage moderate vitamin C intake by dietary sources rather than supplements

24-hour urine calcium (mg calcium per g creatinine): upper level is > 210 in adult men, and > 275 in adult women*

Sodium restriction of 2 g per day or less

Avoid foods high in salt (e.g., canned or processed foods, cheese, pickles, dried meats), and do not add salt to food

Do not restrict calcium intake below recommendations for age and sex

24-hour urine magnesium: lower level < 70 mg per day †

Increase dietary sources of magnesium

Eat fish, nuts, grains, yogurt

Magnesium potassium citrate: two tablets three times per day with meals(each tablet contains 3 mEq of magnesium, 7 mEq of potassium, and 10 mEq of citrate)

Consider magnesium potassium citrate supplementation

24-hour urine citrate: lower level < 450 mg per day in adult men and < 550 mg per day in adult women

Citrate supplementation (available as a potassium, calcium, or sodium salt)

Potassium citrate 10 to 20 mEq orally with meals (prescription required)

Calcium citrate: two 500-mg tablets per day with meals

Sodium salts can increase urinary calcium excretion

Add lemon or lime juice in water

24-hour urine phytates: lower level < 3.8 mg per L of inorganic phosphate, < 0.4 mg per L of inositol phosphate-6

Consider increased fiber intake

Mix one cup concentrated lemon or lime juice per seven cups water

Eat whole grains, legumes, seeds, nuts

Phytate levels depend on methodology used; increasing phytates may also increase oxalate resorption

Calcium phosphate

Stone analysis

Perform a pregnancy test in women (the risk of calcium phosphate stones is increased with pregnancy)

See Urine pH Decrease intake of dairy products, legumes, chocolate, and nuts by about one-third

Minimal human data; acidifying urine decreases the formation of calcium phosphate stones in genetically predisposed rats

Acidify urine

Consider decreasing dietary phosphate intake

Cystine

Stone analysis 24-hour urine cystine levels: upper limit > 250 mg per day

Alkalinize urine

See Urine pH

Avoid dairy products, eggs, legumes, greens

Tiopronin (Thiola): 15 mg per kg in children and 800 to 1,000 mg per day in adults, three divided doses per day

Penicillamine (Cuprimine): 20 to 40 mg per kg per day

Dose of either medication adjusted to maintain urine free cystine concentration < 250 mg per day if possible

Decrease methionine (sulfur) intake

Cystine-binding agents

Struvite (magnesium ammonium phosphate)

Stone analysis or radiography

Acidify urine

See Urine pH

Acetohydroxamic acid: 15 mg per kg in three or four divided doses per day

Consider surgical intervention, especially for stones greater than 10 mm or if there is evidence of ongoing obstruction or infection

Avoid supplemental magnesium (based on animal studies)

Acetohydroxamic acid (Lithostat; urease inhibitor) in patients who cannot tolerate surgical intervention)

Possible surgical intervention

Uric acid

Stone analysis 24-hour urine uric acid: high limit > 800 mg per day History of gout

Decrease protein intake (< 30 percent of total caloric intake)

See Urine pH

Allopurinol: 300 mg orally per day (dose reduction for low estimated glomerular filtration rate)

Increased caffeine intake may reduce stones in persons with diabetes

Reduce or eliminate alcohol intake

For those with diabetes, increase intake of regular or decaffeinated coffee and tea

Alkalinize urine Allopurinol (Zyloprim)


*—Values from Quest Diagnostics in San Jose, Calif.; values may vary by laboratory.

†—Values from the University of California–San Francisco clinical laboratory; values may vary by laboratory.

Information from references 13, and 28 through 33.

Table 5.   Recommendations for the Management of Kidney Stones Based on Stone Type and Urine Properties

View Table

Table 5.

Recommendations for the Management of Kidney Stones Based on Stone Type and Urine Properties

Stone type Diagnostic evaluation Interventions Recommendations Comments

All types

Urine specific gravity > 1.015

Fluid intake (mostly water)

Drink at least 2 L of water per 24 hours

Consider mineral waters, depending on the type of stone

Mineral content of thousands of mineral waters listed at http://www.mineralwaters.org

Body mass index > 25 kg per m2

Weight loss

Promote a healthy diet and exercise

Fasting serum glucose level > 105 mg per dL (5.83 mmol per L), random level > 140 mg per dL (7.77 mmol per L)

Suggestive of insulin resistance or early diabetes mellitus

Promote low-glycemic diet (normal range is laboratory-dependent)

Serum calcium level > 10 mg per dL (2.50 mmol per L)

Consider primary hyperparathyroidism: check intact parathyroid hormone level

Urine pH (dipstick or from 24-hour urine)

Alkalinize urine (i.e., increase urine pH to 6.5 to 7) with dietary changes or oral supplementation, or until 24-hour urine citrate levels are in the normal range

Alkalinize

Potassium citrate: 10 to 20 mEq orally with meals (prescription required)

Calcium citrate: two 500-mg tablets per day with meals (each tablet contains 120 mg of calcium and 6 mEq of bicarbonate)

Acidify urine (i.e., lower urine pH to 7 or less) with dietary changes or oral supplementation

Acidify

Cranberry juice: at least 16 oz per day

Betaine: 650 mg orally three times per day with meals

Calcium oxalate

Stone analysis, if possible

Appropriate protein intake (< 30 percent of total caloric intake)

Take at least 250 mg per dose, or total calcium > 850 mg per day with meals

Thiazide diuretics (e.g., hydrochlorothiazide): 25 to 50 mg per day

Vitamin D increases intestinal calcium absorption, and renal calcium and phosphate absorption

Calcium supplements (calcium citrate is preferred if also trying to raise urine citrate levels)

Check serum 25-hydroxyvitamin D levels (low limit < 30 ng per mL [74.88 nmol per L])

Thiazide diuretics

24-hour urine oxalate: upper level > 40 mg per day

Diet with moderate amount of fruits and vegetables (do not restrict calcium)

Restrict high oxalate foods (more than 6 mg per serving), such as beans, spinach, rhubarb, chocolate, wheat, nuts, and berries

Magnesium potassium citrate: two tablets three times per day with meals (each tablet contains 3 mEq of magnesium, 7 mEq of potassium, and 10 mEq of citrate)

Limit vitamin C to less than 1 g per day

Oxalate restriction is minimally effective and applies primarily to those with genetic mutations in the oxalate transporters

Consider magnesium potassium citrate supplementation

Encourage moderate vitamin C intake by dietary sources rather than supplements

24-hour urine calcium (mg calcium per g creatinine): upper level is > 210 in adult men, and > 275 in adult women*

Sodium restriction of 2 g per day or less

Avoid foods high in salt (e.g., canned or processed foods, cheese, pickles, dried meats), and do not add salt to food

Do not restrict calcium intake below recommendations for age and sex

24-hour urine magnesium: lower level < 70 mg per day †

Increase dietary sources of magnesium

Eat fish, nuts, grains, yogurt

Magnesium potassium citrate: two tablets three times per day with meals(each tablet contains 3 mEq of magnesium, 7 mEq of potassium, and 10 mEq of citrate)

Consider magnesium potassium citrate supplementation

24-hour urine citrate: lower level < 450 mg per day in adult men and < 550 mg per day in adult women

Citrate supplementation (available as a potassium, calcium, or sodium salt)

Potassium citrate 10 to 20 mEq orally with meals (prescription required)

Calcium citrate: two 500-mg tablets per day with meals

Sodium salts can increase urinary calcium excretion

Add lemon or lime juice in water

24-hour urine phytates: lower level < 3.8 mg per L of inorganic phosphate, < 0.4 mg per L of inositol phosphate-6

Consider increased fiber intake

Mix one cup concentrated lemon or lime juice per seven cups water

Eat whole grains, legumes, seeds, nuts

Phytate levels depend on methodology used; increasing phytates may also increase oxalate resorption

Calcium phosphate

Stone analysis

Perform a pregnancy test in women (the risk of calcium phosphate stones is increased with pregnancy)

See Urine pH Decrease intake of dairy products, legumes, chocolate, and nuts by about one-third

Minimal human data; acidifying urine decreases the formation of calcium phosphate stones in genetically predisposed rats

Acidify urine

Consider decreasing dietary phosphate intake

Cystine

Stone analysis 24-hour urine cystine levels: upper limit > 250 mg per day

Alkalinize urine

See Urine pH

Avoid dairy products, eggs, legumes, greens

Tiopronin (Thiola): 15 mg per kg in children and 800 to 1,000 mg per day in adults, three divided doses per day

Penicillamine (Cuprimine): 20 to 40 mg per kg per day

Dose of either medication adjusted to maintain urine free cystine concentration < 250 mg per day if possible

Decrease methionine (sulfur) intake

Cystine-binding agents

Struvite (magnesium ammonium phosphate)

Stone analysis or radiography

Acidify urine

See Urine pH

Acetohydroxamic acid: 15 mg per kg in three or four divided doses per day

Consider surgical intervention, especially for stones greater than 10 mm or if there is evidence of ongoing obstruction or infection

Avoid supplemental magnesium (based on animal studies)

Acetohydroxamic acid (Lithostat; urease inhibitor) in patients who cannot tolerate surgical intervention)

Possible surgical intervention

Uric acid

Stone analysis 24-hour urine uric acid: high limit > 800 mg per day History of gout

Decrease protein intake (< 30 percent of total caloric intake)

See Urine pH

Allopurinol: 300 mg orally per day (dose reduction for low estimated glomerular filtration rate)

Increased caffeine intake may reduce stones in persons with diabetes

Reduce or eliminate alcohol intake

For those with diabetes, increase intake of regular or decaffeinated coffee and tea

Alkalinize urine Allopurinol (Zyloprim)


*—Values from Quest Diagnostics in San Jose, Calif.; values may vary by laboratory.

†—Values from the University of California–San Francisco clinical laboratory; values may vary by laboratory.

Information from references 13, and 28 through 33.

CAN BACTERIAL INFECTION TRIGGER RECURRENCE?

Bacteria exert both pathogenic and protective roles. Struvite stones are associated with recurrent infections because of high urinary pH levels from urease splitting bacteria and the body's inability to rid the urinary tract of bacteria that become embedded in the stones.34

Oxalobacter formigenes is an anaerobic bacterium that colonizes the intestinal tract, where it metabolizes oxalate to formate and carbon dioxide. Absence of O. formigenes colonization predisposes persons to oxalate stones.35 Preliminary studies of O. formigenes ingestion in healthy patients35 and in patients with primary hyperoxaluria36 demonstrated up to a 90 percent decrease in urinary oxalate levels.36 Larger studies of this potential therapy are ongoing.

DOES OBESITY INCREASE RISK AND WILL WEIGHT LOSS REDUCE RISK?

Obesity contributes to risk of kidney stones more than dietary factors. The associated changes in body composition pose biophysical challenges associated with disturbed thermogenesis and dehydration. Because body fat is hydrophobic, the proportion of body water decreases with increasing obesity, which can lead to dehydration.37 Additionally, the decrease in surface area to body volume complicates heat exchange and metabolic rate.38 Obesity is a proinflammatory state associated with electrolyte imbalances and altered urine chemistry. Obese persons with kidney stones are predisposed to hyperuricemia, gout, hypocitraturia, hyperuricosuria, and uric acid stones.39 A recent retrospective analysis found that patients with diabetes and kidney stones excrete more oxalate and have lower urine pH, which is partly a result of higher sulfate excretion and less acid excreted as ammonium ions.40,41 Patients with kidney disease who are obese or have diabetes may have a lesser genetic predisposition to kidney stones and greater responsiveness to environmental modification, such as a healthy diet and hydration.

Weight loss may improve or undermine management of kidney stones, depending on how it is achieved. Weight loss could be detrimental to prevention of kidney stones if associated with a high animal protein diet, laxative abuse, rapid loss of lean tissue, or poor hydration. High acid diets, such as the Atkins diet, increase the risk of uric acid stones. 42 Therefore, diet advice should be based on the type of kidney stone.

SHOULD PATIENTS REDUCE FRUCTOSE INTAKE?

Increased dietary fructose has been associated with up to a 38 percent higher risk of kidney stones. 43 Increased fructose intake increases urinary calcium excretion in persons with magnesium deficiency, and fructose is the only dietary carbohydrate known to raise uric acid levels. Additionally, sugar-sweetened beverages and orange juice have been linked to gout. 44

HOW CAN URINE BE ALKALINIZED (HIGHER URINE PH)? [corrected]

For prevention of calcium oxalate, cystine, and uric acid stones, urine should be alkalinized.45,46 Western diets are characteristically high in acid-producing foods, such as grains, dairy products, legumes, and meat. Alkalinizing urine involves eating a diet high in fruits and vegetables, taking supplemental or prescription citrate, or drinking alkaline mineral waters.1

HOW CAN URINE BE ACIDIFIED (LOWER URINE PH)? [corrected]

For prevention of calcium phosphate and struvite stones, urine should be acidified.47 Cranberry juice or betaine can lower urine pH without the adverse effects associated with acid-producing foods. Although table salt (sodium chloride) also lowers urine pH, it can increase blood pressure, insulin excretion, and urine calcium excretion.

ARE ALTERNATIVE THERAPIES HELPFUL?

Acupuncture and chiropractic manipulation may ease stone passage in patients with nerve impingement. Herbs have been used in acute kidney stone treatment since antiquity, but many uncertainties surround their contemporary use (e.g., quality and safety, interactions with medications or anesthesia, lack of stone-specific effectiveness). However, phytonutrients in green tea, turmeric, and berries may reduce the risk of infection, parsley may promote diuresis, and the traditional herb Agropyron repens may help achieve flushing of the urinary tract.

Data Sources: PubMed searches were completed in Clinical Queries using the key terms kidney stone, nephrolithiasis, chronic kidney disease, pregnancy, children, cystinuria, calcium oxalate, struvite, calcium phosphate, uric acid, magnesium, potassium, citrate, phytate, alkalinizing, aciduria, and uroscopy. PubMed was also searched for specific authors using the key terms, Bushinsky, Coe, Curhan, Moe, and Evans. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Google, Wikipedia, and UpToDate were also searched. Search date: April 17, 2011.

The Authors

LYNDA FRASSETTO, MD, is a professor of medicine at the University of California, San Francisco, School of Medicine.

INGRID KOHLSTADT, MD, MPH, is an associate at Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. At the time this article was written, she was a fellow with the U.S. Food and Drug Administration's Office of Pediatric Therapeutics, Silver Spring, Md.

Address correspondence to Lynda Frassetto, MD, University of California, San Francisco, 505 Parnassus Ave., Campus Box 0126, Room M1201, San Francisco, CA 94143 (e-mail: frassett@gcrc.ucsf.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

The views expressed herein are those of the authors. No endorsement by the U.S. Food and Drug Administration is intended or should be inferred.

REFERENCES

1. Long LO, Park S. Update on nephrolithiasis management. Minerva Urol Nefrol. 2007;59(3):317–325.

2. Acar B, Inci Arikan F, Emeksiz S, Dallar Y. Risk factors for nephrolithiasis in children. World J Urol. 2008;26(6):627–630.

3. Sas DJ, Hulsey TC, Shatat IF, Orak JK. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr. 2010;157(1):132–137.

4. Ross AE, Handa S, Lingeman JE, Matlaga BR. Kidney stones during pregnancy: an investigation into stone composition. Urol Res. 2008;36(2):99–102.

5. Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):804–811.

6. Milliner DS, Murphy ME. Urolithiasis in pediatric patients. May Clin Proc. 1993;68:241.

7. Costa-Bauza A, Ramis M, Montesinos V, et al. Type of renal calculi: variation with age and sex. World J Urol. 2007;25(4):415–21.

8. Scholz D, Schwille PO, Ulbrich D, Bausch WM, Sigel A. Comparison of renal stones and their frequency in a stone clinic: relationship to parameters of mineral metabolism in serum and urine. Urol Res. 1979;7(3):161–70.

9. Pietrow PK, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. 2006;74(1):86–94.

10. Preminger GM, Tiselius HG, Assimos DG, et al.; EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418–2434.

11. Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res. 2010;38(3):147–160.

12. Matlaga BR, Williams JC Jr, Kim SC, et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol. 2006;175(5):1720–1724.

13. Singh A, Alter HJ, Littlepage A. A systematic review of medical therapy to facilitate passage of ureteral calculi. Ann Emerg Med. 2007;50(5):552–563.

14. Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosinsimplifited treatment regimen and health-related quality of life. Urology. 2005;66(4):712–715.

15. Paige NM, Nagami GT. The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc. 2009;84(2):180–186.

16. Saltel E, Angel JB, Futter NG, Walsh WG, O'Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895–1897.

17. Sörgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol. 1985;134(5):871–873.

18. Topamax (topiramate). DailyMed. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7412. Accessed December 30, 2010.

19. Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol. 2000;164(2):438.

20. Siegel WH. Unusual complication of therapy with sulfamethoxazoletrimethoprim. J Urol. 1977;117(3):397.

21. Dick WH, Lingeman JE, Preminger GM, Smith LH, Wilson DM, Shirrell WL. Laxative abuse as a cause for ammonium urate renal calculi. J Urol. 1990;143(2):244–247.

22. Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology. 2008;72(2):278–281.

23. Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006;48(4):555–563.

24. Curhan GC. Epidemiology of stone disease. Urol Clin North Am. 2007;34(3):287–293.

25. Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001;37(2):233–243.

26. American Society of Nephrology. Chronic kidney disease. http://www.asn-online.org/policy_and_public_affairs/docs/ASN%20NKDEP%20CKD%20in%20Primary%20Care%20Presentation%202-08.pdf. Accessed April 12, 2011.

27. Swartz MA, Lydon-Rochelle MT, Simon D, Wright JL, Porter MP. Admission for nephrolithiasis in pregnancy and risk of adverse birth outcomes. Obstet Gynecol. 2007;109(5):1099–1104.

28. Hesse A, Siener R, Heynck H, Jahnen A. The influence of dietary factors on the risk of urinary stone formation. Scanning Microsc. 1993;7(3):1119–1127.

29. Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int. 2004;72(suppl 1):6–10.

30. Serio A, Fraioli A. An observational and longitudinal study on patients with kidney stones treated with Fiuggi mineral water [in Italian]. Clin Ter. 1999;150(3):215–219.

31. Parks JH, Coe FL. Evidence for durable kidney stone prevention over several decades. BJU Int. 2009;103(9):1238–1246.

32. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839–843.

33. Takeuchi H, Ueda M, Satoh M, Yoshida O. Effects of dietary calcium, magnesium and phosphorus on the formation of struvite stones in the urinary tract of rats. Urol Res. 1991;19(5):305–308.

34. Jarrar K, Boedeker RH, Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris). 1996;30(3):112–117.

35. Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009;103(1):18–21.

36. Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70(7):1305–1311.

37. Batmanghelidj F, Kohlstadt I. Water: a driving force in the musculoskeletal system. In: Scientific Evidence for Musculoskeletal, Bariatric and Sports Nutrition. Boca Raton, Fla.: Taylor & Francis; 2006:127–135.

38. Livingston EH, Kohlstadt I. Simplified resting metabolic rate-predicting formulas for normal-sized and obese individuals. Obes Res. 2005;13(7):1255–1262.

39. Ekeruo WO, Tan YH, Young MD, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004;172(1):159–163.

40. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010;183(6):2244–2248.

41. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277–1281.

42. Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab. 1988;66(1):140–146.

43. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int. 2008;73(2):207–212.

44. Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA. 2010;304(20):2270–2278.

45. Trinchieri A, Esposito N, Castelnuovo C. Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate. Arch Ital Urol Androl. 2009;81(3):188–191.

46. Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 1983;24(3):348–352.

47. Pizzarelli F, Peacock M. Effect of chronic administration of ammonium sulfate on phosphatic stone recurrence. Nephron. 1987;46(3):247–252.


Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article